At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Lenvatinib for Prostate Cancer Metastatic and Neuroendocrine Tumors. Active but no longer recruiting, targeting 45 participants across 5 sites.
Detailed Summary
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
Study Details
Timeline
Interventions
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
Lenvatinib 20 mg orally daily.